As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

Name: As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

R. Scott Wright, MD

Professor of Medicine
Department of Cardiovascular Medicine
Cardiovascular Division
Mayo Clinic